… In light of the possibility that our work may pave the way for clinical trials on the effect of
losartan as an antifibrotic therapy to promote optimal skeletal muscle healing, it is important to …

… or sarcopenic patients to benefit from topical therapy. Only in … patients aerosol therapy should
be considered a therapeutic … patients, the possibility to treat non-IPF-ILDs with antifibrotic …

… sarcopenia, is associated with lower health-related quality of life, and greater disability and
mortality risk in chronic kidney disease (CKD) patients [1, … and a possible anti-fibrotic effect on …

… patients treated with steroids showed 22.38% CT, compared to 30% observed in patients
without treatment… to the CT, as patients with steroid treatment showed a higher percentage of …

… Sarcopenia seems to occur by mechanisms that partly are unique to it, and partly are … IL-2,
all of which have been found to be anti-fibrotic cytokines. By contrast, CD4+ Th2 cells promote …

… Senescence-accelerated mouse P8 (SAMP8) mice were used in this study as a sarcopenia
animal model, with the onset at month 8 [17,18]. SAMP8 mice (male, 10 weeks old) were …

… , which is associated with sarcopenia. In this regard, the … -10 secretion, causing an anti-fibrotic
effect, because most organs of … et al suggest the potential of therapeutic use of UC-MNSCs …

… , IL1B and IFNG activities were among the top 10 URs deactivated by combination therapy
which is consistent with the observed anti-fibrotic effects of the combined lifestyle treatment. …

… and is a treatment option for patients with cancer… patients was reported to be 23%–58% [13],
[14], [15]. Currently, there is no established treatment for PPFE, and the efficacy of antifibrotic …

… Therapies endowed with both anti-inflammatory and antifibrotic actions, thus, represent a
compelling strategy to ameliorate age-related conditions. We recently reported that MyMD-1, a …